Meta-Analysis of Gender Differences in Residual Stroke Risk and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
In conclusion, women with AF treated with warfarin have a greater residual risk of CVA/SE and an equivalent major bleeding risk, whereas those treated with NOAC agents deemed superior to warfarin are at equivalent residual risk of CVA/SE and less major bleeding risk compared with men. These results suggest an increased net clinical benefit of NOAC agents compared with warfarin in treating women with AF.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Samir B. Pancholy, Parikshit S. Sharma, Dipti S. Pancholy, Tejas M. Patel, David J. Callans, Francis E. Marchlinski Tags: Arrhythmias and Conduction Disturbances Source Type: research
More News: Accidents | Arrhythmia | Atrial Fibrillation | Bleeding | Cardiology | Coumadin | Heart | Stroke | Study | Warfarin | Women